New implantable 'Cell Pouch' could free diabetics from insulin shots

NCT ID NCT03513939

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a device called the Cell Pouch, which is implanted in the abdomen to create a natural home for donor insulin-producing cells. The goal is to help people with type 1 diabetes who have dangerous low blood sugar episodes. Seventeen participants will receive the implant and donor islet cells while taking immunosuppressive drugs to prevent rejection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Sernova Cell Pouch (implantable device) with donor islet cells
What this could lead to
If it works, this could provide a new way to transplant insulin-producing cells into the body, potentially reducing or eliminating the need for insulin injections in people with type 1 diabetes.
What could go wrong
This is an early Phase 1/2 trial with only 17 participants, so results may not apply to everyone. The procedure requires lifelong immunosuppression, which carries risks like infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Chicago Medical Center

    Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.